Skip to main content

Table 1 Baseline demographics and disease characteristics of the patients, and their study disposition

From: Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

Characteristic APV 600 mg/RTV 100 mg BID (N = 158) APV 1200 mg BID (N = 53)
Age, years   
   Median 40 43
   Range 25 – 63 29 – 62
Gender, No. (%)   
   Male 139 (88) 44 (83)
   Female 19 (12) 9 (17)
Race, No. (%)   
   Caucasian 81 (51) 21 (40)
   Black 58 (37) 20 (38)
   Hispanic 18 (11) 11 (21)
   Asian 1 (<1) 1 (2)
CDC classification   
   Caterory A 74 (47) 29 (55)
   Category B 46 (29) 10 (19)
   Category C 37 (24) 14 (26)
HIV-1 RNA, log10 copies/mL   
   Mean ± SD 4.33 ± 0.58 4.35 ± 0.66
   Median (Range) 4.31 (2.98 – 5.88) 4.38 (2.74 – 5.81)
CD4+ cell count, cells/mm3   
   Mean ± SD 307 ± 187 327 ± 226
   Median (Range) 271 (43 – 948) 255 (35 – 1054)
Premature withdrawal 44 (28) 17 (32)
   Adverse event 11 (7) 4 (8)
   Consent withdrawn 5 (3) 2 (4)
   Lost to follow up 11 (7) 5 (9)
   Insufficient CD4+ response 1 (<1) 0
   Insufficient viral load response 4 (3) 1 (2)
   Protocol-defined virological failure 2 (1) 3 (6)
   Other 10 (6) 2 (4)
  1. Abbreviations: APV, amprenavir; RTV, ritonavir; SD, standard deviation